Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Tech Transfer regular column feature image

Below is Scrip’s regular roundup, including information from Strategic Transactions, of recent technology transfer agreements between companies and academic or other research institutions.

Solidifying a strategy that began with licensing cancer candidate Gem-DHA from privately held CBM BioPharma, Spherix Inc. announced a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

In Brief: Bavarian Nordic’s Board Votes For Private Equity Takeout

 
• By 

The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By 

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company

 
• By 

Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.

Gilead’s Kite Is Latest To Enter In Vivo CAR-T Space With Interius Buy

 

The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.

More from Business

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By 

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.

Finance Watch: BeOne Raises $885m In Imdelltra Royalty Sale

 
• By 

BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.

AbbVie Buys Phase II MDD Candidate From Gilgamesh, But Not The Company

 
• By 

Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.